Penumbra, Inc. (PEN)’s Trend Up, Especially After Today’s Record High Milestone

March 14, 2018 - By Winifred Garcia

The stock of Penumbra, Inc. (NYSE:PEN) reached all time high today, Mar, 14 and still has $133.85 target or 9.00 % above today’s $122.80 share price. This indicates more upside for the $4.19 billion company. This technical setup was reported by If the $133.85 PT is reached, the company will be worth $377.19 million more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events.

The stock decreased 0.32% or $0.4 during the last trading session, reaching $122.8. About 191,335 shares traded. Penumbra, Inc. (NYSE:PEN) has risen 65.49% since March 14, 2017 and is uptrending. It has outperformed by 48.79% the S&P500.

Analysts await Penumbra, Inc. (NYSE:PEN) to report earnings on May, 8. They expect $-0.02 earnings per share, up 80.00 % or $0.08 from last year’s $-0.1 per share. After $0.10 actual earnings per share reported by Penumbra, Inc. for the previous quarter, Wall Street now forecasts -120.00 % negative EPS growth.

Penumbra, Inc. (NYSE:PEN) Ratings Coverage

Among 5 analysts covering Penumbra (NYSE:PEN), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Penumbra had 9 analyst reports since October 13, 2015 according to SRatingsIntel. The stock has “Buy” rating by BMO Capital Markets on Thursday, May 11. The rating was initiated by Wells Fargo with “Outperform” on Tuesday, October 13. The rating was initiated by Bank of America with “Buy” on Wednesday, October 14. The firm has “Buy” rating by Canaccord Genuity given on Tuesday, October 13. The stock has “Overweight” rating by JP Morgan on Tuesday, October 13. The stock has “Buy” rating by BMO Capital Markets on Wednesday, April 12. Canaccord Genuity maintained the stock with “Buy” rating in Monday, November 30 report. The stock of Penumbra, Inc. (NYSE:PEN) has “Neutral” rating given on Tuesday, January 2 by JP Morgan.

More news for Penumbra, Inc. (NYSE:PEN) were recently published by:, which released: “Penumbra, Inc. (PEN) Reports Q4 EPS of $0.25, Beats on Revenues; Offers FY18 …” on February 27, 2018.‘s article titled: “Penumbra, Inc. Reports Fourth Quarter and Full Year 2017 Financial Results” and published on February 27, 2018 is yet another important article.

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company has market cap of $4.19 billion. The firm offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, PX SLIM, and Velocity brands; aspiration based thrombectomy systems and accessory devices under the Penumbra System brand; and revascularization device for mechanical thrombectomy under the 3D brand. It has a 944.62 P/E ratio. It also provides neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400 and Penumbra SMART Coil brands; and neurovascular stents for stent-assisted coiling in large and wide-neck aneurysms under the LIBERTY Stent brand.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: